AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9335522 — intervention group
Group type: COMPARATOR
Intervention: No neoadjuvant chemotherapy
Number of subjects: 292
Study 9335522 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and cisplatin - ongoing phase I/II dose escalation study
Number of subjects: 292
Study 9335522 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and carboplatin - ongoing phase II nonrandomized trial
Number of subjects: 292
Study 8442970 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine with 15‐second laryngoscopy
Number of subjects: 40
Study 8442970 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine with 45‐second laryngoscopy
Number of subjects: 40
Study 8442970 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 15‐second laryngoscopy
Number of subjects: 40
Study 8442970 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 45‐second laryngoscopy
Number of subjects: 40
Study 3767347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (1 g) plus probenecid
Number of subjects: 36
Study 3767347 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil alone
Number of subjects: 36
Study 29943702 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of white blood cell on admission (cutoff points: >8.50×10^9/L)
Number of subjects: 3891
Study 29943702 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of white blood cell on admission (cutoff points: <5.60×10^9/L)
Number of subjects: 3891
Study 29943702 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated white blood cell on admission
Number of subjects: 3891
Study 26054823 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical labor induction in obese women (BMI >30)
Number of subjects: 181
Study 26054823 — intervention group
Group type: COMPARATOR
Intervention: Mechanical labor induction in normal weight women (BMI ≤30)
Number of subjects: 181
Study 26054823 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical labor induction (general)
Number of subjects: 181
Study 25356826 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (50 mg bid for 8 days)
Number of subjects: 14
Study 25356826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 22495111 — intervention group
Group type: EXPERIMENTAL
Intervention: Program of Cardiovascular Disease Prevention (PCVDP) implemented in active clinics
Number of subjects: 66
Study 22495111 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PCVDP)
Number of subjects: 66
Study 19897857 — intervention group
Group type: EXPERIMENTAL
Intervention: CDB-2914 150 mg, in divided doses, administered over three consecutive days starting on Days 21, 49, and 77 after LNG-IUS insertion.
Number of subjects: 136
Study 19897857 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets administered over the same schedule as CDB-2914.
Number of subjects: 136
Study 18604442 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/m2/week i.v. epirubicin for 8 weeks
Number of subjects: 69
Study 18604442 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/m2/week i.v. epirubicin for 8 weeks followed by monthly maintenance therapy for 4-6 months
Number of subjects: 69
Study 18604442 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estramustine phosphate (EMP) at a dose of 840 mg/day with weekly and monthly maintenance epirubicin
Number of subjects: 69
Study 16000426 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR analysis for pneumococci presence in middle ear effusions
Number of subjects: 0
Study 16000426 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional culture for pneumococci presence in middle ear effusions
Number of subjects: 0
Study 16000426 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular typing by amplified fragment length polymorphism
Number of subjects: 0
Study 16000426 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of culture-negative effusions
Number of subjects: 0
Study 12699416 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysed formula (Nutramigen)
Number of subjects: 103
Study 12699416 — intervention group
Group type: COMPARATOR
Intervention: Regular formula
Number of subjects: 103
Study 12699416 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoantibody-positive children
Number of subjects: 103
Study 12699416 — intervention group
Group type: COMPARATOR
Intervention: Autoantibody-negative children
Number of subjects: 103
Study 10228814 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole plus amoxycillin plus tinidazole (OAT) for 2 weeks
Number of subjects: 200
Study 10228814 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole plus amoxycillin (OA) for 2 weeks
Number of subjects: 200
Study 10228814 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole plus clarithromycin plus tinidazole (OCT) for 1 week
Number of subjects: 200
Study 10228814 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole plus clarithromycin plus amoxycillin (OCA) for 1 week
Number of subjects: 200
Study 10228814 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 200
Study 8923867 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (leuprolide acetate, 500 micrograms, sc)
Number of subjects: 25
Study 8923867 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (5000 IU, im)
Number of subjects: 25
Study 1296590 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI of floxuridine (FUDR) 0.3 mg/kg/d for 14 days every 4 weeks
Number of subjects: 166
Study 1296590 — intervention group
Group type: COMPARATOR
Intervention: Control group (observation or systemic fluorouracil)
Number of subjects: 166
Study 3904438 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxicam, 200 mg once a day
Number of subjects: 191
Study 3904438 — intervention group
Group type: COMPARATOR
Intervention: Buffered aspirin, 3,600 mg per day (900 mg four times a day)
Number of subjects: 191
Study 30947294 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model developed using stepwise naïve and mixed-effect logistic regression.
Number of subjects: 5637
Study 30947294 — intervention group
Group type: EXPERIMENTAL
Intervention: Data available in the scheduling system for model development.
Number of subjects: 5637
Study 30947294 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 5637
Study 30099762 — intervention group
Group type: EXPERIMENTAL
Intervention: split‐full‐split thickness flap elevation (test group)
Number of subjects: 40
Study 30099762 — intervention group
Group type: COMPARATOR
Intervention: split thickness approach (control group)
Number of subjects: 40
Study 26309128 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued oxytocin infusion
Number of subjects: 200
Study 26309128 — intervention group
Group type: COMPARATOR
Intervention: Continued oxytocin infusion
Number of subjects: 200
Study 25300266 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 183
Study 25300266 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity physical activity
Number of subjects: 183
Study 25300266 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal sedentary time
Number of subjects: 183
Study 25300266 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity
Number of subjects: 183
Study 25300266 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal physical activity
Number of subjects: 183
Study 22030595 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-controlled feedback
Number of subjects: 62
Study 22030595 — intervention group
Group type: COMPARATOR
Intervention: Constant feedback
Number of subjects: 62
Study 20382973 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol and a metal cannula
Number of subjects: 128
Study 20382973 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol and a balloon catheter
Number of subjects: 128
Study 20382973 — intervention group
Group type: COMPARATOR
Intervention: placebo and a metal cannula
Number of subjects: 128
Study 20382973 — intervention group
Group type: COMPARATOR
Intervention: placebo and a balloon catheter
Number of subjects: 128
Study 20382973 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol
Number of subjects: 128
Study 20382973 — intervention group
Group type: EXPERIMENTAL
Intervention: balloon catheter
Number of subjects: 128
Study 20382973 — intervention group
Group type: EXPERIMENTAL
Intervention: metal cannula
Number of subjects: 128
Study 18596958 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 microg YIC
Number of subjects: 242
Study 18596958 — intervention group
Group type: COMPARATOR
Intervention: Placebo (alum adjuvant)
Number of subjects: 242
Study 18596958 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg YIC
Number of subjects: 242
Study 16005708 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy (DBT) for 52 weeks
Number of subjects: 58
Study 16005708 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 58
Study 12412676 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 4.5 microg
Number of subjects: 357
Study 12412676 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 0.5 mg
Number of subjects: 357
Study 10357919 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-free extracorporeal perfusion with hypertonic, hyperoncotic perfusate containing anti-oxidants (mean volume 1835 +/- 824 ml)
Number of subjects: 35
Study 10357919 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgical management: restorative procedure, thrombectomy or embolectomy)
Number of subjects: 35
Study 8520059 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon-alpha cream (2 x 10(6) IU/g)
Number of subjects: 60
Study 8520059 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllotoxin cream (0.5%)
Number of subjects: 60
Study 8520059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1744356 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol, Cromolyn, Combination of Albuterol and Cromolyn
Number of subjects: 30
Study 1744356 — intervention group
Group type: COMPARATOR
Intervention: None (Control Group II)
Number of subjects: 30
Study 1744356 — intervention group
Group type: COMPARATOR
Intervention: None (Control Group I nonreactors)
Number of subjects: 30
Study 1744356 — intervention group
Group type: EXPERIMENTAL
Intervention: None (Group I reactors)
Number of subjects: 30
Study 6336645 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon hydrochloride 1 mg intravenously
Number of subjects: 14
Study 6336645 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 14
Study 30560738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) for 16 weeks
Number of subjects: 104
Study 30560738 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant medication (ADM) for 16 weeks
Number of subjects: 104
Study 29466592 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Low-Fat (HLF) diet
Number of subjects: 609
Study 29466592 — intervention group
Group type: COMPARATOR
Intervention: Healthy Low-Carbohydrate (HLC) diet
Number of subjects: 609
Study 29466592 — intervention group
Group type: COMPARATOR
Intervention: Comparison between HLF and HLC diets
Number of subjects: 609
Study 29466592 — intervention group
Group type: COMPARATOR
Intervention: Diet-genotype pattern interaction
Number of subjects: 609
Study 29466592 — intervention group
Group type: COMPARATOR
Intervention: Diet-insulin secretion (INS-30) interaction
Number of subjects: 609
Study 29466592 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 609
Study 27197287 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 1434
Study 27197287 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 1434
Study 27197287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1434
Study 25212929 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional video (group A, n = 20)
Number of subjects: 42
Study 25212929 — intervention group
Group type: COMPARATOR
Intervention: No intervention (group B, n = 22)
Number of subjects: 42
Study 23148458 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based decision aid and researcher-led coaching session
Number of subjects: 128
Study 23148458 — intervention group
Group type: COMPARATOR
Intervention: Highway safety video
Number of subjects: 128
Study 19631473 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sham feeding (MSF)
Number of subjects: 13
Study 17688076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitab 150 mg film tablets (test preparation)
Number of subjects: 0
Study 17688076 — intervention group
Group type: COMPARATOR
Intervention: 150 mg film tablets of the originator product (reference preparation)
Number of subjects: 0
Study 17688076 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and reference preparations
Number of subjects: 0
Study 16376753 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated angle-independent motion tracking of mitral annular displacement (MAD)
Number of subjects: 0
Study 16376753 — intervention group
Group type: COMPARATOR
Intervention: Manual tracing of endocardial borders for EF determination
Number of subjects: 0
Study 12075259 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting without balloon predilation
Number of subjects: 130
Study 12075259 — intervention group
Group type: COMPARATOR
Intervention: Conventional stenting after balloon predilation
Number of subjects: 130
Study 12075259 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 130
Study 12075259 — intervention group
Group type: COMPARATOR
Intervention: Conventional stenting
Number of subjects: 130
Study 9584343 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine
Number of subjects: 20
Study 9584343 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 20
Study 7653829 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.15, 0.2, and 0.3 mg/kg)
Number of subjects: 10
Study 7653829 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital (0.75, 1.0, and 1.5 mg/kg)
Number of subjects: 10
Study 7653829 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.75, 1.0, and 1.5 mg/kg)
Number of subjects: 10
Study 2476426 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days of twice daily fractionation (370 cGy/fraction totaling 1480 cGy/course) for three courses (total dose 4440 cGy)
Number of subjects: 142
Study 2476426 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days of twice daily fractionation (370 cGy/fraction totaling 1480 cGy/course)
Number of subjects: 142
Study 1203889 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-dichlorodiammineplatinum(II) alone
Number of subjects: 178
Study 1203889 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-dichlorodiammineplatinum(II) in combination with four other chemotherapeutic agents
Number of subjects: 178
Study 31994309 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil (BXM)
Number of subjects: 0
Study 31994309 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir acid (BXA)
Number of subjects: 0
Study 31473028 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood Asthma Control Test (C‐ACT)
Number of subjects: 179
Study 31473028 — intervention group
Group type: COMPARATOR
Intervention: Control group (no C‐ACT)
Number of subjects: 179
Study 28007633 — intervention group
Group type: EXPERIMENTAL
Intervention: Active commuting
Number of subjects: 188
Study 28007633 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity leisure time physical activity (LTPA)
Number of subjects: 188
Study 28007633 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity leisure time physical activity (LTPA)
Number of subjects: 188
Study 28007633 — intervention group
Group type: COMPARATOR
Intervention: Sedentary controls
Number of subjects: 188
Study 26417092 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo analgesia
Number of subjects: 102
Study 26417092 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid antagonist (naltrexone)
Number of subjects: 102
Study 23690338 — intervention group
Group type: EXPERIMENTAL
Intervention: DRSP/EE-metformin
Number of subjects: 93
Study 23690338 — intervention group
Group type: COMPARATOR
Intervention: DRSP/EE
Number of subjects: 93
Study 23690338 — intervention group
Group type: COMPARATOR
Intervention: metformin
Number of subjects: 93
Study 21765126 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing pump speed (+400 rpm per exercise stage)
Number of subjects: 8
Study 21765126 — intervention group
Group type: COMPARATOR
Intervention: Constant pump speed (≈9775 rpm)
Number of subjects: 8
Study 19747893 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer educational video
Number of subjects: 158
Study 19747893 — intervention group
Group type: COMPARATOR
Intervention: Non‐medical video
Number of subjects: 158
Study 17102005 — intervention group
Group type: EXPERIMENTAL
Intervention: ISNT rule assessment in normal eyes
Number of subjects: 109
Study 17102005 — intervention group
Group type: COMPARATOR
Intervention: ISNT rule assessment in glaucomatous eyes
Number of subjects: 109
Study 17102005 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds ratio for glaucoma associated with violation of the ISNT rule
Number of subjects: 109
Study 15633482 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole breast irradiation at 50 Gy (RT)
Number of subjects: 0
Study 15633482 — intervention group
Group type: COMPARATOR
Intervention: Lumpectomy without RT
Number of subjects: 0
Study 11740347 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus neural mobilization
Number of subjects: 81
Study 11740347 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care
Number of subjects: 81
Study 9164414 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone
Number of subjects: 458
Study 8213508 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol (Omnipaque 350)
Number of subjects: 1390
Study 8213508 — intervention group
Group type: COMPARATOR
Intervention: sodium meglumine diatrizoate (Renografin 76)
Number of subjects: 1390
Study 3316063 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal exposure to the message 'MOMMY AND I ARE ONE' (experimental group)
Number of subjects: 47
Study 3316063 — intervention group
Group type: COMPARATOR
Intervention: Subliminal exposure to the message 'PEOPLE ARE WALKING' (control group)
Number of subjects: 47
Study 29723592 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced Activity Group (N = 19)
Number of subjects: 39
Study 29723592 — intervention group
Group type: COMPARATOR
Intervention: Control Group (N = 20)
Number of subjects: 39
Study 27871268 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg oral tablets, increasing to a maximum of 1000 mg twice daily)
Number of subjects: 524
Study 27871268 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical appearing and tasting tablets)
Number of subjects: 524
Study 25372087 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with low-dose CT
Number of subjects: 0
Study 25372087 — intervention group
Group type: COMPARATOR
Intervention: Screening with radiography
Number of subjects: 0
Study 25372087 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 0
Study 23742102 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiFix (dehydrated human amniotic membrane allografts) with standard care
Number of subjects: 25
Study 23742102 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 25
Study 21338205 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of risk factors for oral cancer (tobacco and alcohol)
Number of subjects: 238
Study 21338205 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of signs of oral cancer (white and red lesions)
Number of subjects: 238
Study 21338205 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher knowledge of risk factors
Number of subjects: 238
Study 18959679 — intervention group
Group type: EXPERIMENTAL
Intervention: iNO + Mil (iNO at approximately 10 ppm and milrinone at 0.5 microg/kg/min)
Number of subjects: 31
Study 18959679 — intervention group
Group type: COMPARATOR
Intervention: iNO
Number of subjects: 31
Study 18959679 — intervention group
Group type: EXPERIMENTAL
Intervention: iNO + Mil
Number of subjects: 31
Study 15879165 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction at 20% of maximal voluntary contraction (MVC) torque
Number of subjects: 16
Study 12859441 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietaria SIT
Number of subjects: 30
Study 12859441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10720167 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg white-tryptophan
Number of subjects: 30
Study 10720167 — intervention group
Group type: COMPARATOR
Intervention: Milk
Number of subjects: 30
Study 8863936 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupationally embedded exercise (dice game)
Number of subjects: 26
Study 8863936 — intervention group
Group type: COMPARATOR
Intervention: Rote exercise (no game)
Number of subjects: 26
Study 1380197 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body cryotherapy
Number of subjects: 8
Study 1380197 — intervention group
Group type: COMPARATOR
Intervention: Whole spine paraffin mud packs
Number of subjects: 8
Study 6831836 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐adrenaline 0.025 micrograms min‐1 kg‐1
Number of subjects: 6
Study 6831836 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐adrenaline 0.05 micrograms min‐1 kg‐1
Number of subjects: 6
Study 6831836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30638738 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acid-enriched meal replacement (EMR)
Number of subjects: 8
Study 30638738 — intervention group
Group type: COMPARATOR
Intervention: High-protein meal replacement beverage (Bariatric Advantage, BA)
Number of subjects: 8
Study 28350273 — intervention group
Group type: EXPERIMENTAL
Intervention: OTSC
Number of subjects: 22
Study 28350273 — intervention group
Group type: COMPARATOR
Intervention: Padlock
Number of subjects: 22
Study 25550337 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg abatacept
Number of subjects: 108
Study 25550337 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/kg abatacept
Number of subjects: 108